156 related articles for article (PubMed ID: 23540777)
21. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
Kuperus JM; Busman RD; Kuipers SK; Broekhuizen HT; Noyes SL; Brede CM; Tobert CM; Lane BR
Urology; 2021 Oct; 156():191-198. PubMed ID: 34217763
[TBL] [Abstract][Full Text] [Related]
23. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.
Böhle A; Leyh H; Frei C; Kühn M; Tschada R; Pottek T; Wagner W; Knispel HH; von Pokrzywnitzki W; Zorlu F; Helsberg K; Lübben B; Soldatenkova V; Stoffregen C; Büttner H;
Eur Urol; 2009 Sep; 56(3):495-503. PubMed ID: 19560257
[TBL] [Abstract][Full Text] [Related]
24. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Haas CR; McKiernan JM
Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299
[TBL] [Abstract][Full Text] [Related]
25. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
[TBL] [Abstract][Full Text] [Related]
26. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
27. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
28. Bladder tumor markers, intravesical therapy and systemic chemotherapy.
Soloway MS
J Urol; 2001 Aug; 166(2):488-9. PubMed ID: 11458052
[No Abstract] [Full Text] [Related]
29. Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study.
Brausi MA; Gontero P; Altieri V; Colombo R; Conti I; Bono AV
Urol Int; 2011; 87(4):470-4. PubMed ID: 22086229
[TBL] [Abstract][Full Text] [Related]
30. Side effects of perioperative intravesical treatment and treatment strategies for these side effects.
Griffin JG; Holzbeierlein J
Urol Clin North Am; 2013 May; 40(2):197-210. PubMed ID: 23540778
[TBL] [Abstract][Full Text] [Related]
31. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
Oh KS; Soto DE; Smith DC; Montie JE; Lee CT; Sandler HM
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):511-7. PubMed ID: 18977098
[TBL] [Abstract][Full Text] [Related]
32. [Intravesical gemcitabine for non-muscle invasive bladder cancer].
Krabbe LM; Schmidt S
Urologe A; 2015 Mar; 54(3):402-5. PubMed ID: 25700862
[No Abstract] [Full Text] [Related]
33. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
[TBL] [Abstract][Full Text] [Related]
34. New agents for bacillus Calmette-Guérin-refractory bladder cancer.
Ahn JJ; McKiernan JM
Urol Clin North Am; 2013 May; 40(2):219-32. PubMed ID: 23540780
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
Di Lorenzo G; Perdonà S; Damiano R; Faiella A; Cantiello F; Pignata S; Ascierto P; Simeone E; De Sio M; Autorino R
Cancer; 2010 Apr; 116(8):1893-900. PubMed ID: 20162706
[TBL] [Abstract][Full Text] [Related]
36. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
Kent E; Sandler H; Montie J; Lee C; Herman J; Esper P; Fardig J; Smith DC
J Clin Oncol; 2004 Jul; 22(13):2540-5. PubMed ID: 15226322
[TBL] [Abstract][Full Text] [Related]
37. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
[TBL] [Abstract][Full Text] [Related]
38. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
Delto JC; Kobayashi T; Benson M; McKiernan J; Abate-Shen C
Oncotarget; 2013 Feb; 4(2):269-76. PubMed ID: 23563166
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
[TBL] [Abstract][Full Text] [Related]
40. The safety and efficacy of gemcitabine for the treatment of bladder cancer.
Schlack K; Boegemann M; Steinestel J; Schrader AJ; Krabbe LM
Expert Rev Anticancer Ther; 2016; 16(3):255-71. PubMed ID: 26781169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
